Peptides for Weight Loss: What the 2026 Trial Data Says

The conversation about peptides for weight loss runs ahead of the evidence almost everywhere except the trial registry. As of April 2026, four peptide medications are approved by the FDA for chronic weight management, one of them is approved in Norway through DMP, and a fifth molecule has produced the largest mean weight-loss percentage ever published in a Phase 2 obesity trial without yet being approved anywhere. Reading peptides for weight loss honestly means reading those numbers in order.

Only four peptide medications are FDA-approved for weight loss as of 2026#

The regulatory perimeter is the most useful starting point, because almost everything sold under the "peptides for weight loss" banner sits outside it. As of April 2026, the FDA has granted approval to four peptide-based medications for chronic weight management: Wegovy injection (semaglutide 2.4 mg weekly), the higher-dose oral semaglutide tablet approved in late 2025 under the national priority voucher program, Zepbound (tirzepatide) approved in November 2023, and Saxenda (liraglutide 3 mg daily). Each of these is a peptide, each carries a defined approved indication, and each has a published label.

These FDA approved weight loss peptides share a structural feature: every one of them activates the GLP-1 receptor. The differences sit in what else they do. Liraglutide is a daily GLP-1 agonist with a relatively short half-life. Semaglutide is a weekly GLP-1 agonist with a long half-life. Tirzepatide is a weekly dual agonist that also activates the GIP receptor. The oral semaglutide tablet is a once-daily formulation that uses the absorption enhancer SNAC to allow systemic uptake of the peptide.

Outside that perimeter, nothing else is approved. AOD-9604, MOTS-c, tesofensine, fragment 176-191, and the various "research peptide" GLP-1 analogs distributed online occupy a different category, with a different evidence base and a different risk profile. The GLP-1 class explainer covers the receptor pharmacology; this guide covers the trial data, the side-effect profile, and the regulatory and grey-market boundary lines.

GLP-1 receptor activity drives the largest weight-loss effects on record#

Mechanistically, the reason peptide medications produce double-digit weight-loss percentages where prior pharmacotherapy struggled to clear 5% comes down to the receptors they engage. GLP-1, GIP, and glucagon are gut and pancreatic peptide hormones that, in their native forms, are released in response to nutrient intake. They have been shown in studies to slow gastric emptying, raise insulin sensitivity, dampen appetite signalling in the hypothalamus, and modulate energy expenditure.

A GLP-1 agonist binds the same GLP-1 receptor that the native hormone binds, but with a half-life measured in days rather than minutes. The result is a near-constant tonic signal across the appetite, glucose-control, and gastric-motility axes. Research suggests the appetite component is the dominant driver of weight loss at clinically used doses: most participants report eating smaller portions, getting full sooner, and finding food less interesting.

A dual GIP and GLP-1 agonist adds a second axis. GIP signalling has been shown to potentiate insulin secretion and act on adipose tissue. The clinical translation, evident in tirzepatide trials, is roughly a 50% larger mean weight-loss effect than semaglutide at the highest approved doses. A triple agonist that adds glucagon-receptor activity, like retatrutide, layers on lipolysis and resting energy expenditure. Each receptor added to the molecule corresponds to a larger mean weight-loss effect in cross-trial data.

Weight-loss cluster receptor map

Trial data ranks tirzepatide above semaglutide above liraglutide for weight loss#

The published trial data on peptides for weight loss is unusually clean, because the pivotal trials were run as randomised double-blind studies against placebo with hard endpoints (percent body-weight change at fixed timepoints). The numbers are extractable in single sentences.

STEP 1 (Wilding et al., NEJM 2021, n=1,961) measured semaglutide 2.4 mg weekly against placebo in adults with overweight or obesity. At 68 weeks, the semaglutide arm lost a mean 14.9% of body weight versus 2.4% on placebo. Roughly 86% of participants lost at least 5%, and 50% lost at least 15%.

SURMOUNT-1 (Jastreboff et al., NEJM 2022, n=2,539) measured three doses of tirzepatide against placebo at 72 weeks. The 5 mg arm lost 15.0%, the 10 mg arm 19.5%, and the 15 mg arm 20.9%. Each dose was statistically separated from placebo and from each other lower dose.

The first head-to-head trial, SURMOUNT-5 (Aronne et al., NEJM 2025), randomised adults with obesity to tirzepatide (up to 15 mg weekly) or semaglutide (up to 2.4 mg weekly) at the highest approved doses for 72 weeks. Tirzepatide produced a mean 20.2% body-weight reduction versus semaglutide's 13.7%. The proportion achieving at least 25% weight loss was 31.6% on tirzepatide versus 16.1% on semaglutide. Klarovel's semaglutide versus tirzepatide head-to-head guide walks through the secondary endpoints in detail.

Liraglutide (Saxenda) trails the weekly compounds. The Saxenda label data reports a mean 8% body-weight reduction at 56 weeks at the 3 mg daily dose, alongside dropout rates that are higher than the weekly comparators. Liraglutide was first to market in this class but is now the lowest-effect option among the FDA-approved weight loss peptides.

Drug	Receptor class	Highest-studied dose	Mean weight loss	Timepoint	Trial
Liraglutide (Saxenda)	GLP-1	3 mg daily	~8%	56 wk	Saxenda label
Semaglutide (Wegovy)	GLP-1	2.4 mg weekly	14.9%	68 wk	STEP 1
Tirzepatide (Zepbound)	GIP + GLP-1	15 mg weekly	20.9%	72 wk	SURMOUNT-1
Retatrutide	GIP + GLP-1 + glucagon	12 mg weekly	24.2%	48 wk	Phase 2 (NCT04881760)

For semaglutide for weight loss specifically, the Klarovel semaglutide complete guide covers titration ladder, label, and adverse-event timing. The named-peptide deep dives on tirzepatide for weight loss and retatrutide cover the same axes for those compounds.

Retatrutide is the next milestone, but it is not yet approved#

Retatrutide is the first triple GIP, GLP-1, and glucagon receptor agonist to complete Phase 2 in obesity. The Phase 2 trial (Jastreboff et al., NEJM 2023, NCT04881760, n=338) reported a mean 24.2% body-weight reduction at 48 weeks at the 12 mg weekly dose, versus 2.1% on placebo. At the time of publication, this was the largest mean weight-loss percentage documented for any pharmacotherapy in a general obesity population.

The Phase 3 program (the TRIUMPH and TRANSCEND trials) is ongoing, with the first Phase 3 readout (TRIUMPH-4) reporting in December 2025. As of April 2026, retatrutide is not approved by the FDA, the European Medicines Agency, or DMP in Norway. Eli Lilly has not yet filed a New Drug Application. Anyone reading "buy retatrutide" content should hold that fact next to the trial numbers, because the regulatory frame is the difference between a prescription medicine and a research-grade compound. Klarovel's research-positioning footing on these compounds is anchored on the disclosures page.

The retatrutide adverse-event profile in Phase 2 was class-typical for GLP-1-axis drugs, with one new signal: dysesthesia (altered skin sensation) appeared in roughly one in five participants at the 12 mg dose, a finding associated with glucagon-receptor activity that has no direct analog in approved GLP-1 medicines. Treatment discontinuation due to adverse events at 12 mg ran roughly four times the placebo rate. Preliminary evidence indicates the efficacy-tolerability tradeoff is real, and is the central question Phase 3 needs to resolve.

Two adjacent compounds in the same generation, cagrilintide (an amylin analog being co-formulated with semaglutide as CagriSema) and survodutide (a GLP-1 / glucagon dual agonist from Boehringer), are also in late-stage trials. Klarovel's deep dives on those compounds will follow as the data publishes.

The next twelve months will reshape the peptides for weight loss landscape in three predictable ways. The full retatrutide Phase 3 readout will produce the first Phase 3 dataset for a triple agonist, with cardiovascular outcomes following a year or two later. Cagrilintide, survodutide, and oral GLP-1 formulations will move from late-stage trials to filing decisions. Real-world durability data will start to answer the maintenance question that STEP 4 raised in 2021 and that no trial has fully closed.

What does not change in that window is the base reading: GLP-1 receptor activity drives the largest mean weight-loss effects in the published literature; the FDA-approved options remain the best-evidenced; the side-effect profile is real and dose-dependent; the maintenance question is structural; and the regulatory perimeter separates approved medicine from research-grade compound. Any peptide for weight loss decision that holds those five facts at once is a defensible decision.

Anyone considering a peptide protocol for weight loss should start with a structured health profile and recent bloodwork, not with a product SKU. Start with the Klarovel questionnaire to see whether a peptide medication fits the profile at all, and which compound the evidence supports.

The peptides people actually run for fat loss are mostly not GLP-1s#

Every major guide to this topic treats "peptides for weight loss" as incretin pharmacology. Wegovy, Zepbound, Mounjaro, Ozempic. That is where the approvals and the effect sizes are, so it is a defensible focus.

It is also not what people building peptide protocols actually select.

Two readings of that, and both matter.

The narrow one is that Klarovel's population is self-selected. People who reach a peptide-protocol platform are, almost by definition, not the people filling a Wegovy prescription. This is a claim about what people choose, not about what works, and the two should never be blurred. GLP-1 receptor agonists remain the most effective pharmacological weight-loss agents available, by a wide margin, and nothing below changes that.

The wider reading is that a whole half of this query goes unanswered. Someone searching for peptides for fat loss and landing on a GLP-1 explainer has not had their question answered if what they meant was the GH-axis and mitochondrial compounds. The table below is that half, with the evidence stated plainly rather than implied.

What the non-GLP-1 fat-loss compounds actually have behind them#

Compound	Human evidence	What it shows	Regulatory status
Tesamorelin	2 phase 3 trials, 806 patients, plus a 50-patient randomised trial	Visceral fat reduced ~15% at 26 weeks and ~18% at 52. In the 2014 trial, visceral adipose tissue fell 34 cm² against a 8 cm² rise on placebo (treatment effect −42 cm², P = 0.005), with no change in subcutaneous fat or BMI	FDA-approved, but only for excess visceral fat in HIV lipodystrophy. Not approved for general obesity
AOD-9604	6 randomised trials, 900+ subjects, including a 536-subject 24-week phase 2b	12-week phase 2 showed 2.6 kg against 0.8 kg on placebo at 1 mg/day oral. The 24-week phase 2b failed its primary endpoint and the obesity programme was terminated in 2007	Not approved. Investigational
MK-677 (ibutamoren)	Multiple randomised trials	Raises GH and IGF-1 and increases fat-free mass, but appetite and fasting glucose rise with it. The engine hard-blocks it above defined HbA1c, glucose and insulin thresholds	Not approved
Ipamorelin, CJC-1295	Limited human trials for body composition specifically	Reliably raise GH pulse amplitude. Body-composition outcomes in humans are thin, and most of what is claimed is extrapolated from GH physiology rather than measured	Not approved
MOTS-c	Preclinical, early human	Mitochondrial-derived peptide with metabolic effects in animal models. Human outcome data is early	Not approved. Recommended by an FDA advisory committee in July 2026 for compounding, which is advice and not approval

Two things are worth naming about that table.

Tesamorelin is the only one with an approval, and the approval is narrow. It is approved for visceral fat in HIV lipodystrophy, not for weight loss in general. The mechanism it demonstrates is also unusual and genuinely interesting: it moved visceral fat without moving subcutaneous fat or BMI, which is not what a scale measures.

AOD-9604 is the cautionary case, and its failure is routinely omitted. A positive 12-week signal did not replicate in a properly powered 24-week trial, and the programme was discontinued. Note the provenance carefully: the phase 2b result was disclosed by the sponsor rather than published in a peer-reviewed journal, so it is weaker as a citation than the tesamorelin data even though it points the other way. Community protocols also use a subcutaneous route at 250 to 500 mcg, while the trials used oral dosing at 0.25 to 1 mg, so the community regimen has no controlled efficacy data behind it at all.

What happens when you stop is part of the decision#

The competitor pages that dominate this query mention discontinuation in a line and move on. It deserves more, because it is the single fact that most changes whether a compound suits a given person.

GLP-1 receptor agonists are continuous-use agents. Klarovel's engine treats semaglutide, tirzepatide and retatrutide as continuous_use_only for this reason: stopping is followed by substantial weight regain, which is a property of the drug class rather than a failure of the person taking it. A protocol that assumes a finite course is the wrong mental model for this class.

Lean mass is the second half of it. Weight lost under aggressive appetite suppression is not all fat, and the proportion that is lean tissue is the part the marketing never quantifies. That is also the strongest argument for the resistance-training and protein floor covered further down, and it is why the engine's GH-axis compounds appear in fat-loss protocols at all: the axis they act on is the one associated with preserving lean tissue, even where the direct human fat-loss evidence is thin.

Peptides for weight loss carry specific contraindications and a real side-effect profile#

Across the GLP-1-class trials, the adverse-event profile is overwhelmingly gastrointestinal and concentrated in the dose-escalation period. Pooled analyses and large self-reported datasets converge on a consistent picture: nausea is the most common event, followed by vomiting, constipation, diarrhoea, and fatigue. A 2026 Communications Medicine analysis of 410,198 self-reported posts from 67,008 users across r/Semaglutide and r/Tirzepatide reported nausea in roughly 37%, fatigue in 17%, vomiting in 16%, constipation in 15%, and diarrhoea in 13%. Users frequently describe the first month as the hardest, with most events fading by week 8, though clinical trial data shows a persistent minority who do not adapt.

The Wegovy 2025 label carries a Boxed Warning for medullary thyroid carcinoma (MTC) and Multiple Endocrine Neoplasia syndrome type 2 (MEN2), based on rodent thyroid C-cell tumour findings whose human relevance is unresolved. The label translates to a categorical contraindication for anyone with a personal or family history of MTC or MEN2. Acute pancreatitis, gallbladder disease, severe gastrointestinal disease, and worsening diabetic retinopathy in patients with type 2 diabetes are documented warnings.

Beyond weight loss, the SELECT trial (Lincoff et al., NEJM 2023, n=17,604) reported a 20% relative reduction in major adverse cardiovascular events with semaglutide 2.4 mg weekly over a mean 39.8 months of follow-up, in adults with overweight or obesity and pre-existing cardiovascular disease. Cardiovascular outcomes data is the input that has shifted GLP-1-class drugs from "weight loss" framing to "metabolic risk reduction" framing in the labels.

Compounded and grey-market peptides shift the risk profile#

The compounded GLP-1 market expanded dramatically during the 2022 to 2024 shortage period when compounding pharmacies were permitted to produce semaglutide and tirzepatide outside the FDA-approved supply chain. Once the FDA declared the shortages resolved, compounded versions of those molecules lost their legal pathway under section 503A of the Federal Food, Drug, and Cosmetic Act. Some operators continued under research-only framing.

A separate category of "research peptides" sits further outside the regulatory perimeter, and most of the "best peptides for fat loss" listicle pages traffic in this tier. AOD-9604, a 16-amino-acid fragment of human growth hormone marketed for fat loss, has produced minimal weight-loss effects in human trials, and the FDA declined to add AOD-9604 to its 503A bulks list in December 2024, removing the most plausible compounding pathway. MOTS-c, tesofensine, fragment 176-191, and similar compounds have early-stage data but no late-stage trials in obesity populations, and their availability runs through research-grade distributors rather than pharmacies. Compared to a GLP-1 weight loss peptide with a published Phase 3 dataset, this category is a different evidence base entirely.

Klarovel's editorial position on this category is that the science and the regulatory frame are different categories of question. The research-positioning disclosures page explains how Klarovel distributes research-grade peptides to vetted distributors for research purposes only, not as approved medicines, and how that framing differs from a prescription pathway. Anyone weighing a compounded or grey-market peptide for weight loss against an approved medication is choosing between two different evidence bases and two different oversight regimes.

A weight-loss peptide protocol is one input, not a standalone fix#

Every pivotal trial in this category combined the medication with structured lifestyle support: calorie-restricted diet (typically 500 kcal/day deficit), at least 150 minutes of moderate-intensity physical activity per week, and some form of behavioural counselling. The 14.9% in STEP 1 and the 20.9% in SURMOUNT-1 are not "drug-only" numbers. They are "drug plus lifestyle" numbers, in carefully recruited trial populations.

Real-world data has begun to land. Adherence in the field tends to be lower than in trials, side-effect-driven discontinuation rates higher, and the maintenance question is unresolved at the population level. The reading that does the most for autonomy is: the medication moves the curve, the lifestyle protocol bends it, and stopping the medication moves it back unless the lifestyle protocol is in place.

Klarovel's view is that a peptide for weight loss decision starts with a structured health profile (current bloodwork, family history, contraindications, prior treatment response), not with a SKU. The Klarovel health questionnaire walks the contraindication screening, surfaces the maintenance question early, and lines up the bloodwork the protocol expects. For anyone already on a protocol, the peptide titration calculator maps the dose escalation that the trial protocols built in to keep the GI events tolerable.

Each weight-loss peptide and comparison, in depth#

This guide is the overview. Each compound and head-to-head below has its own deep dive covering mechanism, the trial data behind it, dosing structure, and where the Norwegian regulatory line falls.

• AOD-9604 peptide: the fat-metabolism fragment guide: AOD-9604 is a 16-amino-acid growth hormone fragment studied for fat metabolism.
• Best Peptides for Fat Loss: What the 2026 Evidence Shows: An evidence-led comparison of GLP-1, dual, and triple agonist peptides for fat loss.
• Cagrilintide Dosage: 2.4 mg Weekly Dose and Titration: Cagrilintide dosage is 2.4 mg once weekly, titrated up from 0.25 mg over 16 weeks.
• GLP-1 class: semaglutide, tirzepatide, retatrutide compared: Semaglutide, tirzepatide, and retatrutide share a pharmacology family but each activates different metabolic receptors.
• GLP-1 Muscle Loss: What the Data Actually Shows in 2026: GLP-1 muscle loss is real but manageable.
• GLP-1 Weight Loss Plateau: Why It Happens and What Works: GLP-1 plateaus arrive near week 60 in most trials.
• How Does Zepbound Work, and How Long Until It Does?: Zepbound acts on two receptors, not one.
• Ozempic Face: What It Is, and Why It Is Not Ozempic: Facial hollowing after rapid weight loss is real, but the paper that named it says it is not a semaglutide effect.
• The Ozempic Pill: Five Semaglutides, Three Shared Doses: Ozempic tablets, Rybelsus and Wegovy tablets are all semaglutide, and three strengths appear on two different products.
• Retatrutide Dosage: The Trial Protocol, Not a Label: Retatrutide has no approved dose.
• Semaglutide (Wegovy, Ozempic): complete evidence guide: Semaglutide is the first widely adopted GLP-1 receptor agonist for obesity and type-2 diabetes.
• Mounjaro, Wegovy and Ozempic in Norway: 2026 Prices: What Mounjaro, Wegovy, Saxenda and Ozempic cost in Norway in 2026, who can get a prescription, and why folketrygden rarely reimburses any of them.
• Tesofensine: The Fourth-Class Weight Loss Peptide Guide: Tesofensine is a triple monoamine reuptake inhibitor that produced 10.6% weight loss in Phase 2.
• Tirzepatide Dosage Chart and Complete Evidence Guide: Every approved tirzepatide dose from 2.5 to 15 mg, which strengths actually had a trial arm, and how mg converts to syringe units.
• Wegovy Dosage Chart, Cost and Side Effects: The Full Guide: The full Wegovy dosage chart week by week, what it costs in the US with and without insurance, side effects at each step, and the STEP and SELECT trial data.
• Wegovy Pill Dosage Chart: Why 25 mg Is Not a Misprint: The oral Wegovy ladder runs 1.5 to 25 mg daily.
• Wegovy Side Effects: How Common, How Long, How Serious: What the Wegovy label and pooled STEP data actually report: incidence per side effect, median duration in days, and the one that does not fade.

More in the weight cluster: Best Peptides for Fat Loss, Tesofensine: The Fourth-Class Weight Loss Peptide Guide, GLP-1 Weight Loss Plateau, Mounjaro, Wegovy and Ozempic in Norway.